Wall Street has perceived the company to have an almost unbreachable defense against competition with its offerings of ...

Guggenheim analyst Vamil Divan maintained a Hold rating on Johnson & Johnson (JNJ – Research Report) yesterday and set a price target of ...

Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the ...

The S&P 500 and Nasdaq both fell by a whopping 1.46 percent and 3.07 percent, respectively, over fears that China is ...

Project Stargate will see companies like Oracle, SoftBank, MGX, and OpenAI commit an initial $100 billion to build data ...

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...

Johnson & Johnson beat Wall Street’s fourth-quarter expectations as strong cancer drug sales compensated for a decline in ...

Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.

Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...

Dwayne "The Rock" Johnson's contract includes a "no-lose" clause that ensures his characters always emerge victorious in ...

Johnson & Johnson (JNJ ... despite the company beating Wall Street expectations on revenue by $70 million and reporting results on earnings per share in line with estimates.